Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Toward Therapies Tailored to Patient Characteristics

Toward Therapies Tailored to Patient Characteristics PISA SYMPOSIUM Silvia Novello, MD, Marina Longo, MD, and Matteo Giaj Levra, MD (J Thorac Oncol. 2007;2: Suppl 1, 38–41) of matching patients with the right drugs, physicians will be able to analyze a patient’s genetic profile and prescribe the best available drug therapy from the very beginning. This will lthough considerable progress has been made in the not only take the guesswork out of finding the right drug, but Adiagnosis and treatment of non-small cell lung cancer also speed up recovery time and increase safety as the (NSCLC) in recent years, this disease is still associated with likelihood of adverse reactions is eliminated. a dismal prognosis. Some improvements have been reported Pharmacogenomics has the potential to dramatically recently after the implementation of third-generation drugs reduce the estimated 100,000 deaths and 2 million hospital- into the clinic. Realistically, we have probably reached a izations that occur each year in the United States as the result plateau in terms of clinical outcomes with the ways in which of adverse drug response. Current methods of dosing based we are currently administering cytotoxic chemotherapy. Fur- on weight and age will be replaced with dosages based on a ther steps could be the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Toward Therapies Tailored to Patient Characteristics

Download PDF
4 pages

Loading next page...
 
/lp/wolters-kluwer-health/toward-therapies-tailored-to-patient-characteristics-88A5K20MlI

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864

Abstract

PISA SYMPOSIUM Silvia Novello, MD, Marina Longo, MD, and Matteo Giaj Levra, MD (J Thorac Oncol. 2007;2: Suppl 1, 38–41) of matching patients with the right drugs, physicians will be able to analyze a patient’s genetic profile and prescribe the best available drug therapy from the very beginning. This will lthough considerable progress has been made in the not only take the guesswork out of finding the right drug, but Adiagnosis and treatment of non-small cell lung cancer also speed up recovery time and increase safety as the (NSCLC) in recent years, this disease is still associated with likelihood of adverse reactions is eliminated. a dismal prognosis. Some improvements have been reported Pharmacogenomics has the potential to dramatically recently after the implementation of third-generation drugs reduce the estimated 100,000 deaths and 2 million hospital- into the clinic. Realistically, we have probably reached a izations that occur each year in the United States as the result plateau in terms of clinical outcomes with the ways in which of adverse drug response. Current methods of dosing based we are currently administering cytotoxic chemotherapy. Fur- on weight and age will be replaced with dosages based on a ther steps could be the

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: May 1, 2007

There are no references for this article.